Pathophysiology of breast cancer ń tọ́ka sí àwọn ìyípadà tí kò bára dé nínú àwọn ìgbésẹ̀ àti ọ̀nà tí kò bára dé tí ó máa ń wáyé nínú ìdàgbàsókè àti ìtẹ̀síwájú àrùn jẹjẹrẹ ọmú.
Ó ní í ṣe pẹ̀lú kíkẹ́kọ̀ọ́ nípa àwọn ohun tó ń ṣẹlẹ̀ nínú ara àti àwọn èròjà tó ń mú kí àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ máa pọ̀ sí i, kí wọ́n sì máa tàn kálẹ̀ nínú ara.
Lára àwọn nǹkan wọ̀nyí ni àbùdá, àbùdá, àti àyíká tó ń mú kí àrùn jẹjẹrẹ ọmú bẹ̀rẹ̀, ó sì ń tẹ̀ síwájú.
Diẹ ninu awọn ayipada pathophysiological bọtini ni akàn ọmu pẹlu:
1. Àwọn àyípadà àbùdá: Àwọn àyípadà nínú àwọn àbùdá kan, irú bí BRCA1 àti BRCA2, lè mú kí ewu àrùn jẹjẹrẹ ọmú pọ̀ sí i.
Wọ́n lè jogún àwọn àyípadà wọ̀nyí tàbí kí wọ́n gba wọ́n nígbà tí ẹnì kan bá wà láàyè.
2. Àìṣòótọ́ nípa èròjà hormone: Àwọn èròjà hormone, àgàgà estrogen, lè kó ipa pàtàkì nínú bí àrùn jẹjẹrẹ ọmú ṣe ń wáyé àti bí àrùn náà ṣe ń pọ̀ sí i.
Bí èròjà hormone kò bá wà níwọ̀ntúnwọ̀nsì tàbí tí estrogen bá pọ̀ ju bó ṣe yẹ lọ, ó lè mú kí àrùn jẹjẹrẹ ọmú pọ̀ sí i.
3. Ìpalára: Ìpalára tó máa ń wáyé déédéé nínú ara ọmú lè mú kí àrùn jẹjẹrẹ máa wáyé nítorí pé ó máa ń mú kí àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ máa dàgbà, kí wọ́n sì máa wà láàyè.
4. Àyíká tí kòkòrò náà wà: Àyíká tó yí kòkòrò náà ká, títí kan ohun tó wà nínú kòkòrò náà, àwọn sẹ́ẹ̀lì tó ń dáàbò bo ara rẹ̀, àti àwọn ohun tó wà nínú ẹ̀jẹ̀, lè nípa lórí bí àrùn jẹjẹrẹ ọmú ṣe ń dàgbà àti bí àrùn náà ṣe ń tàn kálẹ̀.
5. Metastasis: Àrùn jẹjẹrẹ ọmú lè tàn dé àwọn apá mìíràn nínú ara nípasẹ̀ ètò lymphatic tàbí ẹ̀jẹ̀, èyí tó máa ń yọrí sí ìdàgbàsókè àwọn kòkòrò mìíràn nínú àwọn ẹ̀yà ara tó jìnnà.
Mímọ bí àrùn jẹjẹrẹ ọmú ṣe máa ń wáyé ṣe pàtàkì gan-an kí wọ́n tó lè ṣe ààbò tó dára, kí wọ́n lè tètè ṣàwárí àrùn náà, kí wọ́n sì lè ṣe ìtọ́jú rẹ̀.
Underwood SM: Breast cancer in African American women: nursing essentials. ABNF J. , 17 (1): 3-14.
Paliwal SR, Paliwal R, Agrawal GP, Vyas SP: Liposomal nanomedicine for breast cancer therapy. Nanomedicine (Lond). 2011, 6 (6): 1085-100.
Rauch GM, Adrada BE: Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation. Magn Reson Imaging Clin N Am. 2018, 26 (2): 273-280.
Wei H, Wang H, Ji Q, Sun J, Tao L, Zhou X: NRBP1 is downregulated in breast cancer and NRBP1 overexpression inhibits cancer cell proliferation through Wnt/β-catenin signaling pathway. Onco Targets Ther. 2015, 8 (): 3721-30.
Eden JA: Human breast cancer stem cells and sex hormones--a narrative review. Menopause. 2010, 17 (4): 801-10.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14 (24): 8010-8.
Ìyàsímímọ́: ìtọ́jú ìlera
Oju opo wẹẹbu yii ni a pese fun eto-ẹkọ ati awọn idi alaye nikan ati pe ko ṣe agbekalẹ pese imọran iṣoogun tabi awọn iṣẹ ọjọgbọn.
A ò gbọ́dọ̀ lo ìsọfúnni tó wà nínú ìwé náà láti ṣe àyẹ̀wò tàbí láti wo àìsàn tàbí àìsàn kan wò, àwọn tó bá sì ń wá ìmọ̀ràn nípa ìṣègùn fúnra wọn gbọ́dọ̀ bá dókítà tó ní ìwé àṣẹ sọ̀rọ̀.
Jọwọ ṣe akiyesi nẹtiwọọki neural ti o ṣe agbejade awọn idahun si awọn ibeere, jẹ pataki ti ko tọ nigbati o ba de si akoonu nọmba. Fun apẹẹrẹ, nọmba awọn eniyan ti a ṣe ayẹwo pẹlu aisan kan pato.
Nigbagbogbo wa imọran ti dokita rẹ tabi olupese ilera ti o ni oye miiran nipa ipo iṣoogun kan. Maṣe gbagbe imọran iṣoogun ọjọgbọn tabi idaduro ni wiwa rẹ nitori nkan ti o ti ka lori oju opo wẹẹbu yii. Ti o ba ro pe o le ni pajawiri iṣoogun, pe 911 tabi lọ si yara pajawiri ti o sunmọ julọ lẹsẹkẹsẹ. Ko si ibatan dokita-aisan ti a ṣẹda nipasẹ oju opo wẹẹbu yii tabi lilo rẹ. Bẹni BioMedLib tabi awọn oṣiṣẹ rẹ, tabi ẹnikẹni ti o ṣe alabapin si oju opo wẹẹbu yii, ṣe eyikeyi awọn aṣoju, ṣalaye tabi tumọ, pẹlu ọwọ si alaye ti a pese nibi tabi lilo rẹ.
Ìyàsímímọ́: ẹ̀tọ́ ọmọnìyàn
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) n pese atunṣe fun awọn onihun aṣẹ-aṣẹ ti o gbagbọ pe ohun elo ti o han lori Intanẹẹti ṣe ilokulo awọn ẹtọ wọn labẹ ofin aṣẹ-aṣẹ AMẸRIKA.
Ti o ba gbagbọ ni igbagbọ to dara pe eyikeyi akoonu tabi ohun elo ti o wa ni asopọ pẹlu oju opo wẹẹbu wa tabi awọn iṣẹ ṣe ilokulo aṣẹ-aṣẹ rẹ, iwọ (tabi aṣoju rẹ) le firanṣẹ akiyesi kan si wa ti o beere pe a yọ akoonu tabi ohun elo naa kuro, tabi idilọwọ iraye si rẹ.
A gbọdọ firanṣẹ awọn iwifunni ni kikọ nipasẹ imeeli (wo abala "Ibaṣepọ" fun adirẹsi imeeli).
DMCA nilo pe akiyesi rẹ ti ilokulo aṣẹ-aṣẹ ti a fi ẹsun kan pẹlu alaye wọnyi: (1) apejuwe ti iṣẹ ti o ni aṣẹ-aṣẹ ti o jẹ koko-ọrọ ti ilokulo ti a fi ẹsun kan; (2) apejuwe ti akoonu ti a fi ẹsun kan ati alaye ti o to lati gba wa laaye lati wa akoonu naa; (3) alaye olubasọrọ fun ọ, pẹlu adirẹsi rẹ, nọmba foonu ati adirẹsi imeeli; (4) alaye nipasẹ rẹ pe o ni igbagbọ rere pe akoonu ni ọna ti o ni ẹsun ti ko ni aṣẹ nipasẹ eni aṣẹ-aṣẹ, tabi aṣoju rẹ, tabi nipasẹ iṣẹ ti ofin eyikeyi;
(5) ìpolongo kan láti ọ̀dọ̀ rẹ, tí o fìdí rẹ̀ múlẹ̀ lábẹ́ ìjìyà ẹ̀rí èké, pé ìsọfúnni tó wà nínú ìkéde náà tọ̀nà àti pé o ní àṣẹ láti mú kí àwọn ẹ̀tọ́ ọmọnìyàn tí wọ́n sọ pé wọ́n ti rú ṣẹ ṣẹ;
ati (6) ibuwọlu ti ara tabi itanna ti ẹni ti o ni aṣẹ tabi eniyan ti o ni aṣẹ lati ṣiṣẹ ni orukọ ẹni ti o ni aṣẹ.
Ti o ko ba ṣafikun gbogbo alaye ti o wa loke le ja si idaduro ti ṣiṣe ẹdun rẹ.
Ìfọ̀rọ̀wérọ̀
Jọwọ fi imeeli ranṣẹ si wa pẹlu eyikeyi ibeere / imọran.
What is pathophysiology of breast cancer?
Pathophysiology of breast cancer refers to the abnormal changes in the normal physiological processes and mechanisms that occur in the development and progression of breast cancer.
It involves the study of the underlying biological and molecular mechanisms that lead to the uncontrolled growth and spread of cancer cells in the breast tissue.
This includes the genetic, epigenetic, and environmental factors that contribute to the initiation, promotion, and progression of breast cancer.
Some of the key pathophysiological changes in breast cancer include:
1. Genetic mutations: Mutations in certain genes, such as BRCA1 and BRCA2, can increase the risk of developing breast cancer.
These mutations can be inherited or acquired during a person's lifetime.
2. Hormonal imbalances: Hormones, particularly estrogen, can play a role in the development and growth of breast cancer.
An imbalance in hormone levels or exposure to excess estrogen can increase the risk of breast cancer.
3. Inflammation: Chronic inflammation in the breast tissue can contribute to the development of breast cancer by promoting the growth and survival of cancer cells.
4. Tumor microenvironment: The environment surrounding the tumor, including the extracellular matrix, immune cells, and blood vessels, can influence the growth and spread of breast cancer.
5. Metastasis: Breast cancer can spread to other parts of the body through the lymphatic system or bloodstream, leading to the formation of secondary tumors in distant organs.
Understanding the pathophysiology of breast cancer is crucial for developing effective prevention, early detection, and treatment strategies.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Ní nǹkan bí
BioMedLib nlo awọn kọnputa adaṣe (awọn alugoridimu ẹkọ ẹrọ) lati ṣe agbejade awọn tọkọtaya ibeere ati idahun.
A bẹrẹ pẹlu awọn atẹjade biomedical miliọnu 35 ti PubMed/Medline. Pẹlupẹlu, awọn oju-iwe wẹẹbu ti RefinedWeb.
